X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs MYLAN (US) - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   MYLAN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
MYLAN
Dec-18
AUROBINDO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8093,275-   
Low Rs5041,803-   
Sales per share (Unadj.) Rs281.11,507.1-  
Earnings per share (Unadj.) Rs41.440.9-  
Cash flow per share (Unadj.) Rs50.9323.1-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.41,630.4-  
Shares outstanding (eoy) m585.88514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.7 138.6%   
Avg P/E ratio x15.962.0 25.6%  
P/CF ratio (eoy) x12.97.9 164.2%  
Price / Book Value ratio x3.31.6 211.5%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6301,306,361 29.4%   
No. of employees `00017.335.0 49.5%   
Total wages/salary Rs m21,3080-   
Avg. sales/employee Rs Th9,500.722,154.9 42.9%   
Avg. wages/employee Rs Th1,229.40-   
Avg. net profit/employee Rs Th1,397.9601.6 232.4%   
INCOME DATA
Net Sales Rs m164,666775,420 21.2%  
Other income Rs m1,0200-   
Total revenues Rs m165,686775,420 21.4%   
Gross profit Rs m37,718200,650 18.8%  
Depreciation Rs m5,580145,189 3.8%   
Interest Rs m77737,295 2.1%   
Profit before tax Rs m32,38018,166 178.2%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183-2,890 -283.1%   
Profit after tax Rs m24,22921,056 115.1%  
Gross profit margin %22.925.9 88.5%  
Effective tax rate %25.3-15.9 -158.8%   
Net profit margin %14.72.7 541.9%  
BALANCE SHEET DATA
Current assets Rs m121,878432,994 28.1%   
Current liabilities Rs m86,806315,700 27.5%   
Net working cap to sales %21.315.1 140.8%  
Current ratio x1.41.4 102.4%  
Inventory Days Days13084 155.4%  
Debtors Days Days6893 73.3%  
Net fixed assets Rs m81,037150,419 53.9%   
Share capital Rs m586413 141.9%   
"Free" reserves Rs m116,2180-   
Net worth Rs m116,804838,863 13.9%   
Long term debt Rs m4,512905,402 0.5%   
Total assets Rs m211,0522,250,156 9.4%  
Interest coverage x42.71.5 2,868.9%   
Debt to equity ratio x01.1 3.6%  
Sales to assets ratio x0.80.3 226.4%   
Return on assets %11.82.6 456.9%  
Return on equity %20.72.5 826.4%  
Return on capital %27.43.2 860.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m46,0270-   
CASH FLOW
From Operations Rs m19,548161,132 12.1%  
From Investments Rs m-19,570-83,288 23.5%  
From Financial Activity Rs m8,642-75,065 -11.5%  
Net Cashflow Rs m8,9221,335 668.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.81 Rs / USD

Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: DR. DATSONS LABS  SUVEN LIFESCIENCES  PANACEA BIOTECH  VENUS REMEDIES  CADILA HEALTHCARE  



Today's Market

Sensex Ends 318 Points Lower; Auto and Metal Stocks Witness Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance (The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks (Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 18, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS